Increased β‑catenin and c-myc expression predict aggressive growth of non-functioning pituitary adenomas: An assessment using a tissue microarray-based approach

Liu,Chunhui; Wu,Youtu; Yu,Shengyuan; Bai,Jiwei; Li,Chuzhong; Wu,Dan; Zhang,Yazhuo

doi:10.3892/mmr.2017.6169

Increased β‑catenin and c-myc expression predict aggressive growth of non-functioning pituitary adenomas: An assessment using a tissue microarray-based approach

Authors:
- Chunhui Liu
- Youtu Wu
- Shengyuan Yu
- Jiwei Bai
- Chuzhong Li
- Dan Wu
- Yazhuo Zhang
View Affiliations

Affiliations: Neurosurgical Department, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, P.R. China, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100050, P.R. China, Neurological Department, Beijing Renhe Hospital, Beijing 102699, P.R. China
Published online on: February 6, 2017 https://doi.org/10.3892/mmr.2017.6169
Pages: 1793-1799

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non-functional pituitary adenomas (NFPAs) account for 80% of pituitary adenomas with the majority of these exhibiting recurrences post-surgery. Overexpression of β-catenin and c‑myc is common in numerous invasive tumors. The present study sought to investigate the correlation of β‑catenin and c‑myc expression levels with aggressive growth and recurrence of NFPAs, using immunohistochemical examination of tissue microarrays. Tissue microarrays comprised 212 NFPAs specimens and 10 healthy specimens as controls. NFPAs were categorized as non‑aggressive or aggressive. Immunohistochemical examination was performed to determine the expression of β‑catenin and c‑myc. Correlation of the expression levels of β‑catenin and c‑myc with clinicopathological parameters, including aggressiveness and recurrence, were assessed by univariate, multivariate and logistic regression analysis. Increased expression of β‑catenin and c‑myc was detected in the majority of aggressive NFPAs specimens (71.1 and 88.7%, respectively). There was a significant positive correlation between β‑catenin and c‑myc expression and aggressiveness [P=0.001, Odds Ratio (OR)=4.011; P<0.001, OR=30.833]. Only β‑catenin expression demonstrated a significant correlation with recurrence in NFPAs (P=0.021, OR=2.571). β‑catenin and c‑myc were demonstrated to be potential biomarkers for aggressive NFPAs and in the future, β-catenin may serve as a marker for aggressive behavior and recurrence in NFPAs.

View Figures

View References

1	Scheithauer BW, Gaffey TA, Lloyd RV, Sebo TJ, Kovacs KT, Horvath E, Yapicier O, Young WF Jr, Meyer FB, Kuroki T, et al: Pathobiology of pituitary adenomas and carcinomas. Neurosurgery. 59:341–353. 2006. View Article : Google Scholar
2	Saeger W, Lüdecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ and Petersenn S: Pathohistological classification of pituitary tumors: 10 years of experience with the german pituitary tumor registry. Eur J Endocrinol. 156:203–216. 2007. View Article : Google Scholar : PubMed/NCBI
3	Brochier S, Galland F, Kujas M, Parker F, Gaillard S, Raftopoulos C, Young J, Alexopoulou O, Maiter D and Chanson P: Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery: A study of 142 patients. Eur J Endocrinol. 163:193–200. 2010. View Article : Google Scholar : PubMed/NCBI
4	Clevers H and Nusse R: Wnt/beta-catenin signaling and disease. Cell. 149:1192–1205. 2012. View Article : Google Scholar : PubMed/NCBI
5	Herr P, Hausmann G and Basler K: WNT secretion and signalling in human disease. Trends Mol Med. 18:483–493. 2012. View Article : Google Scholar : PubMed/NCBI
6	Polakis P: The many ways of Wnt in cancer. Curr Opin Genet Dev. 17:45–51. 2007. View Article : Google Scholar : PubMed/NCBI
7	Jin T, George Fantus I and Sun J: Wnt and beyond Wnt: Multiple mechanisms control the transcriptional property of beta-catenin. Cell Signal. 20:1697–1704. 2008. View Article : Google Scholar : PubMed/NCBI
8	Michl P, Barth C, Buchholz M, Lerch MM, Rolke M, Holzmann KH, Menke A, Fensterer H, Giehl K, Löhr M, et al: Claudin-4 expression decreases invasiveness and metastatic potential of pancreatic cancer. Cancer Res. 63:6265–6271. 2003.PubMed/NCBI
9	Sodir NM, Swigart LB, Karnezis AN, Hanahan D, Evan GI and Soucek L: Endogenous myc maintains the tumor microenvironment. Genes Dev. 25:907–916. 2011. View Article : Google Scholar : PubMed/NCBI
10	Wright JB, Brown SJ and Cole MD: Upregulation of c-MYC in cis through a large chromatin loop linked to a cancer risk-associated single-nucleotide polymorphism in colorectal cancer cells. Mol Cell Biol. 30:1411–1420. 2010. View Article : Google Scholar : PubMed/NCBI
11	Lin CY, Lovén J, Rahl PB, Paranal RM, Burge CB, Bradner JE, Lee TI and Young RA: Transcriptional amplification in tumor cells with elevated c-myc. Cell. 151:56–67. 2012. View Article : Google Scholar : PubMed/NCBI
12	Wu Y, Bai J, Li Z, Wang F, Cao L, Liu C, Yu S, Yu G and Zhang Y: Low expression of secreted frizzled-related protein 4 in aggressive pituitary adenoma. Pituitary. 18:335–342. 2015. View Article : Google Scholar : PubMed/NCBI
13	Formosa R, Gruppetta M, Falzon S, Santillo G, DeGaetano J, Xuereb-Anastasi A and Vassallo J: Expression and clinical significance of Wnt players and survivin in pituitary tumours. Endocr Pathol. 23:123–131. 2012. View Article : Google Scholar : PubMed/NCBI
14	Hong L, Wu Y, Feng J, Yu S, Li C, Wu Y, Li Z, Cao L, Wang F and Zhang Y: Overexpression of the cell adhesion molecule claudin-9 is associated with invasion in pituitary oncocytomas. Hum Pathol. 45:2423–2429. 2014. View Article : Google Scholar : PubMed/NCBI
15	Wilson CB: A decade of pituitary microsurgery. The Herbert Olivecrona lecture. J Neurosurg. 61:814–833. 1984. View Article : Google Scholar : PubMed/NCBI
16	Knosp E, Steiner E, Kitz K and Matula C: Pituitary adenomas with invasion of the cavernous sinus space: A magnetic resonance imaging classification compared with surgical findings. Neurosurgery. 33:610–617. 1993. View Article : Google Scholar : PubMed/NCBI
17	Rosenquist M: 14-3-3 proteins in apoptosis. Braz J Med Biol Res. 36:403–408. 2003. View Article : Google Scholar : PubMed/NCBI
18	Kopp C, Theodorou M, Poullos N, Astner ST, Geinitz H, Stalla GK, Meyer B, Molls M, Nieder C and Grosu AL: Fractionated stereotactic radiotherapy in the treatment of pituitary adenomas. Strahlenther Onkol. 189:932–937. 2013. View Article : Google Scholar : PubMed/NCBI
19	Monga SP: β-Catenin signaling and roles in liver homeostasis, injury, and tumorigenesis. Gastroenterology. 148:1294–1310. 2015. View Article : Google Scholar : PubMed/NCBI
20	Cohen JB, Geyer SM, Lozanski G, Zhao W, Heerema NA, Hall NC, Nagar VA, Hemminger JA, Jones JA, Porcu P, et al: Complete response to induction therapy in patients with myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival. Cancer. 120:1677–1685. 2014. View Article : Google Scholar : PubMed/NCBI
21	Prensner JR, Chen W, Han S, Iyer MK, Cao Q, Kothari V, Evans JR, Knudsen KE, Paulsen MT, Ljungman M, et al: The long non-coding RNA PCAT-1 promotes prostate cancer cell proliferation through cMyc. Neoplasia. 16:900–908. 2014. View Article : Google Scholar : PubMed/NCBI
22	Lin YU, Wu T, Yao Q, Zi S, Cui L, Yang M and Li J: LGR5 promotes the proliferation of colorectal cancer cells via the Wnt/β-catenin signaling pathway. Oncol Lett. 9:2859–2863. 2015.PubMed/NCBI
23	Chiurillo MA: Role of the Wnt/β-catenin pathway in gastric cancer: An in-depth literature review. World J Exp Med. 5:84–102. 2015. View Article : Google Scholar : PubMed/NCBI
24	Soutto M, Romero-Gallo J, Krishna U, Piazuelo MB, Washington MK, Belkhiri A, Peek RM Jr and El-Rifai W: Loss of TFF1 promotes Helicobacter pylori-induced β-catenin activation and gastric tumorigenesis. Oncotarget. 6:17911–17922. 2015. View Article : Google Scholar : PubMed/NCBI
25	Ho SK, Thike AA, Cheok PY, Tse GM and Tan PH: Phyllodes tumours of the breast: The role of CD34, vascular endothelial growth factor and β-catenin in histological grading and clinical outcome. Histopathology. 63:393–406. 2013. View Article : Google Scholar : PubMed/NCBI
26	Simpson DJ, Hibberts NA, McNicol AM, Clayton RN and Farrell WE: Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island. Cancer Res. 60:1211–1216. 2000.PubMed/NCBI
27	Lee EH, Kim KH, Kwon JH, Kim HD and Kim YZ: Results of immunohistochemical staining of cell-cycle regulators: The prediction of recurrence of functioning pituitary adenoma. World Neurosurg. 81:563–575. 2014. View Article : Google Scholar : PubMed/NCBI
28	O'Sullivan EP, Woods C, Glynn N, Behan LA, Crowley R, O'Kelly P, Smith D, Thompson CJ and Agha A: The natural history of surgically treated but radiotherapy-naïve nonfunctioning pituitary adenomas. Clin Endocrinol (Oxf). 71:709–714. 2009. View Article : Google Scholar : PubMed/NCBI
29	Wang EL, Qian ZR, Rahman MM, Yoshimoto K, Yamada S, Kudo E and Sano T: Increased expression of HMGA1 correlates with tumour invasiveness and proliferation in human pituitary adenomas. Histopathology. 56:501–509. 2010. View Article : Google Scholar : PubMed/NCBI
30	Dallapiazza RF, Grober Y, Starke RM, Laws ER Jr and Jane JA Jr: Long-term results of endonasal endoscopic transsphenoidal resection of nonfunctioning pituitary macroadenomas. Neurosurgery. 76:42–53. 2015. View Article : Google Scholar : PubMed/NCBI
31	Chang EF, Zada G, Kim S, Lamborn KR, Quinones-Hinojosa A, Tyrrell JB, Wilson CB and Kunwar S: Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas. J Neurosurg. 108:736–745. 2008. View Article : Google Scholar : PubMed/NCBI